These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

709 related articles for article (PubMed ID: 25653088)

  • 1. Histone deacetylase inhibitors in hematological malignancies and solid tumors.
    Chun P
    Arch Pharm Res; 2015 Jun; 38(6):933-49. PubMed ID: 25653088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone Deacetylase Inhibitors as Anticancer Drugs.
    Eckschlager T; Plch J; Stiborova M; Hrabeta J
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.
    Mottamal M; Zheng S; Huang TL; Wang G
    Molecules; 2015 Mar; 20(3):3898-941. PubMed ID: 25738536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors.
    Slingerland M; Guchelaar HJ; Gelderblom H
    Anticancer Drugs; 2014 Feb; 25(2):140-9. PubMed ID: 24185382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?
    Amin SA; Adhikari N; Jha T
    Pharmacol Res; 2017 Aug; 122():8-19. PubMed ID: 28501516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of resistance to histone deacetylase inhibitors.
    Lee JH; Choy ML; Marks PA
    Adv Cancer Res; 2012; 116():39-86. PubMed ID: 23088868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
    Singh AK; Bishayee A; Pandey AK
    Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylases and epigenetic therapies of hematological malignancies.
    Mercurio C; Minucci S; Pelicci PG
    Pharmacol Res; 2010 Jul; 62(1):18-34. PubMed ID: 20219679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors in the treatment of lymphoma.
    Lemoine M; Younes A
    Discov Med; 2010 Nov; 10(54):462-70. PubMed ID: 21122478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer activities of histone deacetylase inhibitors.
    Bolden JE; Peart MJ; Johnstone RW
    Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors in cancer therapy.
    Lane AA; Chabner BA
    J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of histone deacetylases and their inhibitors in cancer biology and treatment.
    Beumer JH; Tawbi H
    Curr Clin Pharmacol; 2010 Aug; 5(3):196-208. PubMed ID: 20406169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
    Duvic M; Dimopoulos M
    Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Histone deacetylase inhibitors - molecular mechanisms of actions and clinical applications].
    Grabarska A; Dmoszyńska-Graniczka M; Nowosadzka E; Stepulak A
    Postepy Hig Med Dosw (Online); 2013 Aug; 67():722-35. PubMed ID: 24018438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors in the treatment of hematological malignancies.
    Petrella A; Fontanella B; Carratù A; Bizzarro V; Rodriquez M; Parente L
    Mini Rev Med Chem; 2011 Jun; 11(6):519-27. PubMed ID: 21561404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases.
    Riester D; Hildmann C; Schwienhorst A
    Appl Microbiol Biotechnol; 2007 Jun; 75(3):499-514. PubMed ID: 17377788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents.
    Cappellacci L; Perinelli DR; Maggi F; Grifantini M; Petrelli R
    Curr Med Chem; 2020; 27(15):2449-2493. PubMed ID: 30332940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.
    Hymes KB
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):98-109. PubMed ID: 20371442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
    Noureen N; Rashid H; Kalsoom S
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.